End-to-End Capability
From nucleic acid design to antigen production and delivery formulation.
Flexible Modalities
Support for mRNA, protein subunit, and viral vector vaccine platforms.
In-House Manufacturing
Reagents, instruments, and production facilities under direct quality control.
Regulatory Readiness
GMP-aligned processes supporting IND filing documentation (ICH Q7 / FDA 21 CFR Part 211 framework).
Fast Turnaround
Integrated antigen design, nucleic acid synthesis, and vector construction — reducing typical lead times from 8–12 weeks to under 4 weeks.
Stay updated with the latest industry news and expert insights.
Subscribe now to receive:
● Industry updates
● Exclusive expert insights and analysis
Enter your email to stay ahead!
